Clinical Trials | December 07, 2025
Bayer reports promising results for low-dose pediatric MRI contrast agent
MRI is particularly valuable in pediatric care due to its non-invasive nature
MRI is particularly valuable in pediatric care due to its non-invasive nature
Terray and BMS aim to accelerate small molecule drug discovery by harnessing EMMI’s integrated experimental and AI capabilities
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
Growing patent filings and tier-2 innovators reflect expanding national research base
The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
The company is excluding data from the affected sites to maintain the study's integrity
Seeing well-controlled Phase 3 data that shows a marked slowing of lesion growth in Stargardt disease is deeply encouraging
This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA
Fresh Phase 1b/2a data highlight the strength of the iberdomide + daratumumab + dexamethasone combination in transplant-deferred or ineligible NDMM
Subscribe To Our Newsletter & Stay Updated
